Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00093600
Other study ID # NOVARTIS-CPKC412A2106
Secondary ID UCLA-0308139-01C
Status Completed
Phase Phase 1
First received
Last updated
Start date February 2004
Est. completion date June 2011

Study information

Verified date March 2015
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.


Description:

OBJECTIVES: Primary - Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia. - Compare the pharmacokinetics of these regimens in these patients. Secondary - Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients. - Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens. OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups. - Induction therapy: - Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity. - Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity. In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy. - Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity. After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months.


Recruitment information / eligibility

Status Completed
Enrollment 69
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility DISEASE CHARACTERISTICS: - Histologically confirmed acute myeloid leukemia (AML) - Newly diagnosed disease - No history of or newly diagnosed myelodysplastic syndromes, history of myeloproliferative disease, or secondary AML - No CNS malignancy PATIENT CHARACTERISTICS: Age - 18 to 60 Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - Not specified Hepatic - AST and ALT = 1.5 times upper limit of normal (ULN) - Bilirubin = 1.5 times ULN - No active viral hepatitis Renal - Creatinine = 1.5 times ULN - No chronic renal disease Cardiovascular - Ejection fraction = 50% by MUGA or echocardiogram - No congestive heart failure - No myocardial infarction within the past 6 months - No poorly controlled hypertension - No other cardiovascular disease Pulmonary - No pulmonary infiltrate, including those suspected to be infectious - Patients with pulmonary infection whose clinical symptoms have resolved are eligible provided there are no residual pulmonary infiltrates on chest x-ray Other - No gastrointestinal impairment or disease that would preclude absorption of study drugs - No uncontrolled diabetes - No active uncontrolled infection - No other disease, except carcinoma in situ, that would preclude study participation - No other severe or uncontrolled medical condition that would preclude study participation - HIV negative - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy - At least 5 days since prior growth factors - No concurrent biological response modifiers Chemotherapy - No prior chemotherapy - No other concurrent chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy except radiation castration - No concurrent radiotherapy Surgery - More than 14 days since prior surgical procedure except central venous catheter placement or other minor procedure (e.g., skin biopsy) Other - More than 30 days since prior investigational agents - No other concurrent anticancer agents - No other concurrent investigational drugs

Study Design


Intervention

Drug:
cytarabine

daunorubicin hydrochloride

midostaurin


Locations

Country Name City State
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Mainz
United States Dana Faber Cancer Institute Boston Massachusetts
United States Wayne State University/Karmanos Cancer Institute Detroit Michigan
United States MD Anderson Cancer Center/University of Texas Houston Texas
United States Jonsson Comprehensive Cancer Center at UCLA Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Germany, 

References & Publications (1)

Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diag — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Response (CR) rate cycle = between 28 days and 42 days in duration cycle 1, day 14, cycle day 21 - 28, end of each cycle
Secondary CR rate by FLT3 mutation and treatment arm CR:cycle 1, day 14, cycle day 21 - 28, end of each cycle, FLT3: monthly
Secondary Overall survival by FLT3 mutation status time of death of any cause(FLT# - minthly)
See also
  Status Clinical Trial Phase
Recruiting NCT04240002 - A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Completed NCT02626715 - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS Phase 2
Completed NCT05488613 - Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Terminated NCT02927938 - Leukemia Stem Cell Detection in Acute Myeloid Leukemia Phase 3
Completed NCT01772953 - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT Phase 2
Recruiting NCT03188874 - Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Completed NCT00071006 - AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT04079296 - A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) Phase 1/Phase 2
Completed NCT04509622 - A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) Phase 3
Withdrawn NCT03699384 - Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Phase 1/Phase 2
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Completed NCT02252107 - 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 Phase 2
Terminated NCT01463410 - Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler N/A
Completed NCT01242774 - Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Phase 1
Terminated NCT02134782 - Yoga Fatigue Study N/A
Completed NCT01685619 - AML-MDS Novel Prognostic Tests Clinical Study
Completed NCT03625505 - A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04266795 - A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy Phase 2